Daniel P. Barry

Daniel P. Barry

Auto-generated profile, based on publicly available information

Daniel P. Barry

Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2017 in Gut
Verified
Journal Article
Closed access
PDF file
JSJohanna C Sierra
Johanna C Sierra
MAMohammad Asim
Mohammad Asim
TVThomas G Verriere
Thomas G Verriere
MPM Blanca Piazuelo
M Blanca Piazuelo
GSGiovanni Suarez
Giovanni Suarez
KWKeith T. T Wilson
Keith T. T Wilson
Objective: Gastric cancer is the third leading cause of cancer death worldwide and infection byHelicobacter pyloriis the strongest risk factor. We have reported increased epidermal growth factor receptor (EGFR) phosphorylation in theH. pylori-induced human carcinogenesis cascade, and association with DNA damage. Our goal was to determine the role of EGFR activation in gastric carcinogenesis.Design: We evaluated gefitinib, a specific EGFR inhibitor, in chemoprevention ofH. pylori-induced gastric inflammation and cancer development. Mice with genetically targeted epithelial cell-specific deletion ofEgfr(EfgrΔepimice) were also used.Results: In C57BL/6 mice, gefitinib decreasedCxcl1andCxcl2expression by gastric epithelial cells, myeloperoxidase-positive inflammatory cells in the mucosa and epithelial DNA damage induced byH. pyloriinfection. Similar reductions in chemokines, inflammatory cells and DNA damage occurred in infectedEgfrΔepiversusEgfrfl/flcontrol mice. InH. pylori-infected transgenic insulin-gastrin (INS-GAS) mice and gerbils, gefitinib treatment markedly reduced dysplasia and carcinoma. Gefitinib blockedH. pylori-induced activation of mitogen-activated protein kinase 1/3 (MAPK1/3) and activator protein 1 in gastric epithelial cells, resulting in inhibition of chemokine synthesis. MAPK1/3 phosphorylation and JUN activation was reduced in gastric tissues from infected wild-type and INS-GAS mice treated with gefitinib and in primary epithelial cells fromEfgrΔepiversusEgfrfl/flmice. Epithelial EGFR activation persisted in humans and mice afterH. pylorieradication, and gefitinib reduced gastric carcinoma in INS-GAS mice treated with antibiotics.Conclusions: These findings suggest that epithelial EGFR inhibition represents a potential strategy to prevent development of gastric carcinoma inH. pylori-infected individuals.

8 October 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
DPDina Polosukhina
Dina Polosukhina
KSKshipra Singh
Kshipra Singh
MAMohammad Asim
Mohammad Asim
DBDaniel P. Barry
Daniel P. Barry
MAMargaret M. Allaman
Margaret M. Allaman
LCLori Coburn
Lori Coburn

10 September 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
LCLori Coburn
Lori Coburn
KSKshipra Singh
Kshipra Singh
MAMohammad Asim
Mohammad Asim
DBDaniel P. Barry
Daniel P. Barry
MAMargaret M. Allaman
Margaret M. Allaman
KWKeith T. T Wilson
Keith T. T Wilson

26 October 2016 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
KSKshipra Singh
Kshipra Singh
NANicole T Al-Greene
Nicole T Al-Greene
TVThomas G Verriere
Thomas G Verriere
LCLori Coburn
Lori Coburn
MAMohammad Asim
Mohammad Asim
KWKeith T. T Wilson
Keith T. T Wilson
Solute carrier family 7 member 2 (SLC7A2) is an inducible transporter of the semi-essential amino acid L-arginine (L-Arg), which has been implicated in immune responses to pathogens. We assessed the role of SLC7A2 in murine infection with Citrobacter rodentium, an attaching and effacing enteric pathogen that causes colitis. Induction of SLC7A2 was upregulated in colitis tissues, and localized predominantly to colonic epithelial cells. Compared to wild-type mice, Slc7a2–/–mice infected with C. rodentium had improved survival and decreased weight loss, colon weight, and histologic injury; this was associated with decreased colonic macrophages, dendritic cells, granulocytes, and Th1 and Th17 cells. In infected Slc7a2–/–mice, there were decreased levels of the proinflammatory cytokines G-CSF, TNF-α, IL-1α, IL-1β, and the chemokines CXCL1, CCL2, CCL3, CCL4, CXCL2, and CCL5. In bone marrow chimeras, the recipient genotype drove the colitis phenotype, indicative of the importance of epithelial, rather than myeloid SLC7A2. Mice lacking Slc7a2 exhibited reduced adherence of C. rodentium to the colonic epithelium and decreased expression of Talin-1, a focal adhesion protein involved in the attachment of the bacterium. The importance of SLC7A2 and Talin-1 in the intimate attachment of C. rodentium and induction of inflammatory response was confirmed in vitro, using conditionally-immortalized young adult mouse colon (YAMC) cells with shRNA knockdown of Slc7a2 or Tln1. Inhibition of L-Arg uptake with the competitive inhibitor, L-lysine (L-Lys), also prevented attachment of C. rodentium and chemokine expression. L-Lys and siRNA knockdown confirmed the role of L-Arg and SLC7A2 in human Caco-2 cells co-cultured with enteropathogenic Escherichia coli. Overexpression of SLC7A2 in human embryonic kidney cells increased bacterial adherence and chemokine expression. Taken together, our data indicate that C. rodentium enhances its own pathogenicity by inducing the expression of SLC7A2 to favor its attachment to the epithelium and thus create its ecological niche. Intestinal infections by attaching and effacing (A/E) bacteria widely impact human health, with major social and economic repercussions. Mucosal immunity plays a critical role in determining the outcome of these infections. The amino acid L-arginine regulates inflammatory responses to bacterial pathogens. We studied the role of the L-arginine transporter solute carrier family 7 member 2 (SLC7A2) during infection with the A/E pathogen Citrobacter rodentium. SLC7A2 is induced in colonic epithelial cells during the infection and facilitates the intimate attachment of the bacteria, thus initiating the inflammatory response of the infected mucosa. These data were confirmed in vitro using C. rodentium-infected mouse cells and human colonic epithelial cells infected with enteropathogenic Escherichia coli. Our work describes a mechanism by which A/E bacteria manipulate host response to favor their colonization, thereby positioning SLC7A2 as an unrecognized therapeutic target to limit infection with enterobacteria.

22 June 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
YLYvonne L. Latour
Yvonne L. Latour
JSJohanna C. Sierra
Johanna C. Sierra
JFJordan L. Finley
Jordan L. Finley
MAMohammad Asim
Mohammad Asim
DBDaniel P. Barry
Daniel P. Barry
KWKeith T. T Wilson
Keith T. T Wilson
Macrophages play a crucial role in the inflammatory response to the human stomach pathogen Helicobacter pylori , which infects half of the world’s population and causes gastric cancer. Recent studies have highlighted the importance of macrophage immunometabolism in their activation state and function. We have demonstrated that the cysteine-producing enzyme cystathionine γ-lyase (CTH) is upregulated in humans and mice with H. pylori infection. Here, we show that induction of CTH in macrophages by H. pylori promoted persistent inflammation. Cth –/– mice had reduced macrophage and T cell activation in H. pylori –infected tissues, an altered metabolome, and decreased enrichment of immune-associated gene networks, culminating in decreased H. pylori –induced gastritis. CTH is downstream of the proposed antiinflammatory molecule, S -adenosylmethionine (SAM). Whereas Cth –/– mice exhibited gastric SAM accumulation, WT mice treated with SAM did not display protection against H. pylori –induced inflammation. Instead, we demonstrated that Cth -deficient macrophages exhibited alterations in the proteome, decreased NF-κB activation, diminished expression of macrophage activation markers, and impaired oxidative phosphorylation and glycolysis. Thus, through altering cellular respiration, CTH is a key enhancer of macrophage activation, contributing to a pathogenic inflammatory response that is the universal precursor for the development of H. pylori –induced gastric disease.

10 November 2024 in Oncogene
Verified
Journal Article
Open access
PDF file
KMKara M. McNamara
Kara M. McNamara
JSJohanna C. Sierra
Johanna C. Sierra
YLYvonne L. Latour
Yvonne L. Latour
CHCaroline V. Hawkins
Caroline V. Hawkins
MAMohammad Asim
Mohammad Asim
KWKeith T. T Wilson
Keith T. T Wilson
Helicobacter pylori is the primary cause of gastric cancer, and there is a need to discover new molecular targets for therapeutic intervention in H. pylori disease progression. We have previously shown that spermine oxidase (SMOX), the enzyme that catabolizes the back-conversion of the polyamine spermine to spermidine, is upregulated during infection and is associated with increased cancer risk in humans. We sought to determine the direct role of SMOX in gastric carcinogenesis during H. pylori infection. In this study, we demonstrate that transgenic FVB/N insulin-gastrin (INS-GAS) mice that develop gastric carcinoma with H. pylori infection were protected from cancer development with Smox deletion. RNA sequencing revealed that genes associated with the immune system and cancer were downregulated in the infected Smox –/– mice. Furthermore, there was a decrease in cell proliferation and DNA damage in infected Smox –/– animals. There was significant generation of adducts of the highly reactive electrophile acrolein, a byproduct of SMOX activity, in gastric tissues from H. pylori-infected humans and wild-type, but not Smox –/– mice. Genetic deletion of Smox in murine organoids or chemical inhibition of SMOX in human gastric epithelial cells significantly reduced generation of acrolein induced by H. pylori. Additionally, acrolein-induced DNA damage in gastric epithelial cells was ablated with the electrophile scavenger 2-hydroxybenzylamine (2-HOBA). Gastric acrolein adduct levels were attenuated in infected INS-GAS mice treated with 2-HOBA, which exhibit reduced gastric carcinoma. These findings implicate SMOX and acrolein in H. pylori-induced carcinogenesis, thus indicating their potential as therapeutic targets.